跳转至内容
Merck
所有图片(2)

主要文件

查看所有文档

S9318

Sigma-Aldrich

Sandoz 58-035

>98% (HPLC), powder, acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor

别名:

3-[癸基二甲基甲硅烷基] -N- [2-（4-甲基苯基）-1-苯乙基]丙酰胺, SA 58-035

登录查看公司和协议定价
所有图片(2)

About This Item

经验公式（希尔记法）:
C30H47NOSi
CAS号:
78934-83-5
分子量:
465.79
MDL號碼:
MFCD00161339
分類程式碼代碼:
41121801
PubChem物質ID:
24278227
NACRES:
NA.77

产品名称

Sandoz 58-035, >98% (HPLC), powder

品質等級

100

化驗

>98% (HPLC)

形狀

powder

顏色

white

溶解度

DMSO: 16 mg/mL
H2O: insoluble

起源

Novartis

儲存溫度

2-8°C

SMILES 字串

CCCCCCCCCC[Si](C)(C)CCC(=O)NC(Cc1ccc(C)cc1)c2ccccc2

InChI

1S/C30H47NOSi/c1-5-6-7-8-9-10-11-15-23-33(3,4)24-22-30(32)31-29(28-16-13-12-14-17-28)25-27-20-18-26(2)19-21-27/h12-14,16-21,29H,5-11,15,22-25H2,1-4H3,(H,31,32)

InChI 密鑰

NBYATBIMYLFITE-UHFFFAOYSA-N

基因資訊

human ... SOAT1(6646)
rat ... Soat1(81782)

應用

Sandoz 58-035 用于诱导小鼠腹腔巨噬细胞中未折叠蛋白反应（UPR）和模式识别受体（PRR）的同时激活。3

生化／生理作用

Sandoz 58-035 抑制胆固醇酯的积累，抑制培养物中动脉平滑肌细胞 95％ 的胆固醇酯化。1它不影响肠道甘油三酯代谢。2
酰基辅酶 A：胆固醇酰基转移酶（ACAT）抑制剂。

特點和優勢

该化合物由 Novartis 开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number
065M4602V
122M4604V
022M4605V
103K4708

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Makiko Fukunaga et al.
Experimental cell research, 316(19), 3272-3281 (2010-09-22)
Mast cell is one of the central effectors in inflammatory responses. Recent studies suggest that a promising therapeutic approach for various inflammatory immune diseases, including rheumatoid arthritis, multiple sclerosis, and type I allergies, is to inhibit mast cell growth and/or
C Mazière et al.
Biochimica et biophysica acta, 1300(1), 30-34 (1996-03-29)
The effects of interleukin 1beta (IL1) in the range of concentration of 10-30 ng/ml on cholesterol metabolism were investigated in the monocyte-macrophage cell line J774. IL1 enhanced cholesterol esterification by [14C]oleic acid and acyl-coenzyme A cholesterol acyl transferase activity in
K Cianflone et al.
Atherosclerosis, 107(2), 125-135 (1994-06-01)
This study examines the effects of extracellular albumin on hepatic apo B-100 metabolism. To do so, a transformed human liver cell line, HepG2, was used as a hepatocyte model and the concentration of albumin in the medium was varied between
H Hakamata et al.
Arteriosclerosis and thrombosis : a journal of vascular biology, 14(11), 1860-1865 (1994-11-01)
The species difference in the turnover rates of the cholesteryl ester (CE) cycle in macrophage foam cells (MFC) was examined in mice and rats. MFC were induced by acetyl-LDL and pulsed with [3H]oleate, followed by a chase with [14C]oleate. The
Charlotte P J Talbot et al.
Atherosclerosis, 274, 23-28 (2018-05-11)
Obesity is associated with a lower HDL-mediated cholesterol efflux from macrophages and a higher CETP (cholesteryl ester transfer protein) activity, but effects of weight loss are not clear. In addition, associations with visceral and subcutaneous adipose tissue are not known.
查看所有相关文献

商品

Cholesterol Esterification

Cholesterol undergoes esterification to improve transport. Cholesterol esters are more easily packaged into the interior of lipoproteins - increasing the quantity that can be readily transported in the blood stream.

Antilipemic Agents

Randomized controlled clinical studies have suggested 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are effective in both primary and secondary prevention of cardiovascular disease (CVD) events.

Antilipemic Agents

Randomized controlled clinical studies have suggested 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are effective in both primary and secondary prevention of cardiovascular disease (CVD) events.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门